Annual Scientific Meeting

Visit GI Cancer Trials 

Collaborate. Accelerate. Improve Outcomes.

The 28th Annual Scientific Meeting (ASM) will be held on the lands of the Muwinina people in Nipaluna / Hobart from 24 to 27 November 2026.

This year’s meeting will focus on addressing the key challenges in GI cancer research and care. With a strong emphasis on innovation, collaboration, and equitable trial access, the ASM will bring together leading researchers, clinicians, and collaborative partners to share insights that translate into better outcomes for people affected by GI cancer – ensuring that no one is left behind.


The 28th ASM is especially significant, marking our first meeting as GI Cancer Trials and collaboration with CommNETs and AANZGOSA, creating an even richer forum for connection and impact.

We look forward to welcoming you to picturesque Nipaluna / Hobart for what promises to be another fantastic and engaging event.

Photo of Associate Professor Margaret Lee

Associate Professor

Margaret Lee

Co-Convenor

Photo of Associate Professor Sina Vatandoust

Associate Professor

Sina Vatandoust

Co-Convenor

Abstracts

Submission deadline:

Monday 10 August 2026,

9:00am AEST

Registration

Early bird registration deadline:

Monday 31 August 2026,

11:59pm AEST

Awards

Submission deadline:

Monday 7 September 2026,

9:00am AEST

New Concepts Symposium

Submission deadline:

Monday 7 September 2026,

9:00am AEST

Thank you to our 2026 sponsors

Merck logo
BMS logo
MSD logo
Exelixis logo
View all sponsors
Become a sponsor

The 28th GI Cancer Trials ASM is supported by the Tasmanian Government through the Business Events Attraction Fund (BEAF). The Tasmanian Government’s BEAF is delivered through Business Events Tasmania.

We are proud that the 28th GI Cancer Trials ASM has ‘Consumers Included’ status provided by Cancer Voices ensuring that the perspectives of patients, survivors, carers and other members of the public affected by cancer are part of the planning and program of the conference. Read more

Consumers provide firsthand experiences and insights into the challenges and issues they face during their cancer journey. These real-world perspectives can guide researchers and clinicians in identifying gaps in care and improving the quality of life.

The active participation of consumers can lead to more relevant research questions, more effective study designs, and better communication of research findings to the public.

Involving consumers in research enhances the quality and relevance of the discussions, promotes patient-centred care, and ultimately contributes to the overall goal of improving cancer care and outcomes. It also ensures that the research and discussions are aligned with the needs and perspectives of those directly affected by cancer.

What our past attendees say

“I found the entire conference to be very interesting. I really enjoyed the panel discussions, learning about the patient’s perspective and hearing about the attempts to improve long term outcomes for patients. I will definitely be recommending this ASM to my colleagues.”

Adele O'Brien

Eastern Health Clinical School, VIC

“I had the pleasure of meeting some inspiring people at the

meeting, networking with fellow study coordinators and nurses and have come back to work with a renewed enthusiasm for my role in trials, and how I can make small changes within the team to improve care before, during and after treatment.”

Charmayne Chorlton

Tweed Valley Hospital, NSW

“The conference gave me a rare and valuable window into the complexity of decision making across the patient care journey. The strong translational focus and numerous MDT and case-based sessions demonstrated the intricate considerations involved in selecting therapies and sequencing treatments in real-world contexts.”

Kristen Needham

Olivia Newton-John Cancer Research Institute, VIC

“Attending the conference provided valuable knowledge on cutting-edge research and collaborative opportunities. I enjoyed listening and reading about the emerging therapies for GI cancers, advances in immunotherapy and precision

medicine and the strategies for improving clinical trial design and patient recruitment.”

Meghan McCotter

Toowoomba Hospital, QLD

“The program was engaging, featuring expert presentations on emerging therapies, diagnostic advances, and evolving best practice guidelines. I have encouraged other colleagues to attend next year!”

Michelle Cybulski

Royal Brisbane & Women's Hospital, QLD

“It was a great opportunity to learn from and engage with leading experts in the field, especially from the international speakers. The supportive atmosphere made networking easy and enjoyable, with the right mix of informative sessions and networking opportunities.”

Poppy Sharman

Royal Brisbane & Women's Hospital, QLD

“The meeting was an outstanding educational and developmental opportunity. It deepened my understanding of multidisciplinary GI cancer care, sharpened my research focus, and strengthened my professional network.”

Dr Rathin Gosavi

Cabrini Health, VIC

“It was great to see the work both Australia and New Zealand are doing to support Indigenous

participation in clinical trials and improve access to care. A key theme was the importance of understanding cultural needs and building trust within communities, and it was encouraging to see how much effort has gone into strengthening these relationships.”

Therese Kong

Auckland City Hospital, NZ

“The knowledge, networks, and insights I gained at this meeting will have a meaningful, lasting impact on my professional development and my ability to contribute to high-quality, patient-centred, and equitable oncology research at my institution.”

Yijia Chen

St Vincent's Hospital Melbourne, VIC

Aboriginal and Torres Strait Islanders flags

GI Cancer Trials acknowledges the Traditional Custodians of Country throughout Australia. We pay our respects to Elders both past and present, and extend that respect to all First Nations people we meet and engage with in our work and purpose.

We acknowledge the enduring connections First Nations peoples have with Country, culture, community and kin, and recognise these as fundamental to healing and wellbeing. These connections are especially important in the cancer journey.

We are committed to learning from the great diversity of First Nations voices, knowledge systems and lived experiences as we work to develop and conduct cancer research that is culturally safe, inclusive and equitable for all communities.

Pride flag

GI Cancer Trials benefits from a diverse and collaborative workplace and membership. We are committed to be open and inclusive, and we seek, welcome and value different perspectives.

Across our workplace, membership and committees, we are proactively fostering an environment and culture that values, respects and is safe for people of any age, gender, ethnicity, cultural or socioeconomic background, faith or religion, sexual orientation, geographic location or disability.